Acessibilidade / Reportar erro

Glucantime resistant Leishmania promastigotes are sensitive to pentostam

Abstracts

Growth inhibition in vitro tests were used to study the susceptibility to pentostam of different Leishmania strains involved in cutaneous and mucocutaneos leishmaniasis - one glucantime sensitive strain, three naturally glucantime resistant strains and one glucantime resistant line developed by in vitro drug exposure. Contrasting with the high degree , of glucantime resistance, all strains were sensitive to pentostam. These differences suggest that there is some relationship between chemical structure and in vitro activity for these antimonial compounds. These data justify a clinical re-evaluation to compare therapeutic efficacy of glucantime and pentostam in the treatment of leishmaniasis.

Leishmania Pentavalent antimonial compounds; Growth inhibition; Experimental chemotherapy


Diferentes amostras de Leishmania foram analisadas quanto à susceptibilidade in vitro ao pentostam - uma cepa de L. (V) braziliensis considerada sensível ao glucantime, três cepas (duas L. (V) braziliensis e uma L. (L) amazonensis) consideradas naturalmente resistentes ao glucantime, uma linhagem resistente (L. (V) guyanensis) selecionada in vitro pela exposição em alta concentração de droga. A elevada sensibilidade destas amostras em contraposição à resistência observada para o glucantime sugere existir relação entre a estrutura química e a atividade destes compostos. Estes dados indicam a necessidade de ima avaliação comparativa de atividade clínica do pentostam e do glucantime no tratamento da leishmaniose.

Leishmania; compostos antimoniais pentavalentes; Inibição de crescimento; Infecção experimental


ARTICLES

Glucantime resistant Leishmania promastigotes are sensitive to pentostam

Elizabeth Spangler Andrade Moreira; Juliana Becattini Guerra; Maria de Lourdes Petrillo-Peixoto

Adress to correspondence Adress to correspondence: Dra. Elizabeth S.A. Moreira. Laboratório de Biologia de Microbiologia/ICB/UFMG CP: 2486 31271- 970 Belo Horizonte, MG

ABSTRACT

Growth inhibition in vitro tests were used to study the susceptibility to pentostam of different Leishmania strains involved in cutaneous and mucocutaneos leishmaniasis - one glucantime sensitive strain, three naturally glucantime resistant strains and one glucantime resistant line developed by in vitro drug exposure. Contrasting with the high degree , of glucantime resistance, all strains were sensitive to pentostam. These differences suggest that there is some relationship between chemical structure and in vitro activity for these antimonial compounds. These data justify a clinical re-evaluation to compare therapeutic efficacy of glucantime and pentostam in the treatment of leishmaniasis.

Keywords:Leishmania Pentavalent antimonial compounds. Growth inhibition. Experimental chemotherapy.

RESUMO

Diferentes amostras de Leishmania foram analisadas quanto à susceptibilidade in vitro ao pentostam - uma cepa de L. (V) braziliensis considerada sensível ao glucantime, três cepas (duas L. (V) braziliensis e uma L. (L) amazonensis) consideradas naturalmente resistentes ao glucantime, uma linhagem resistente (L. (V) guyanensis) selecionada in vitro pela exposição em alta concentração de droga. A elevada sensibilidade destas amostras em contraposição à resistência observada para o glucantime sugere existir relação entre a estrutura química e a atividade destes compostos. Estes dados indicam a necessidade de ima avaliação comparativa de atividade clínica do pentostam e do glucantime no tratamento da leishmaniose.

Palavras-chave:Leishmania. compostos antimoniais pentavalentes. Inibição de crescimento. Infecção experimental.

Full text available only in PDF format.

Texto completo disponível apenas em PDF.

Recebido para publicação em 28/05/92.

Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG.

Research supported by PRPq/UFMG.

This work was performed in partial fulfillment of the requirements for the Ph.D. (E.S.A.M.) at Instituto de Microbiologia da Universidade Federal do Rio de Janeiro.

  • 1. Allen S. Neal RA. The in vitro susceptibility of macrophages infected with amastigotes of Leishmania spp to pentavalent antimonial drugs and other compounds with special relevance to cutaneous isolates. In: Leishmaniasis Hart D T (ed) Plenum Publishing Corporation p.711-720, 1989.
  • 2. Barbieri CL, Figueiredo EN, Gorin PAS, Travassos LR. The effect of mannan-coupled antimony on Leishmania infected macrophages. Memórias do Instituto Oswaldo Cruz 85 (suppl.I):103, 1990.
  • 3. Berman JD, Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Reviews of Infectious Diseases 10:560- 586, 1988.
  • 4. Beverley SM. Gene amplification in Leishmania Annual Review of Microbiology 45:417-444,1991.
  • 5. Bryceson ADM, Chulay JD, Ho M, Mugambii M, Were JB, Muigai K, Chunge C, Gachihi G, Meme J, Anabwani G, Bhatt SM. Visceral leismaniasis unresponsive to antimonial drugs. 1-clinical immunological studies. Transactions Royal Society of Tropical Medicine and Hygiene 79:699-704, 1985.
  • 6. Bryceson ADM, Chulay JD, Mugambii M, Were JB, Gachihi G, Chunge C, Muigai R, Bhatt SM, Ho M, Spencer HC, Meme J, Anabwani G. Visceral leismaniasis unresponsive to antimonial drugs. II- Response to high dosage sodium stibogluconate or prolonged treatment with pentamidine. Transactions Royal Society of Tropical Medicine and Hygiene 79:705-714, 1985.
  • 7. Callahan HL, Beverley SM. Heavy metal resistance: a new role for P-glycoproteins in Leishmania The Journal of Biological Chemistry 266:18427-18430, 1991.
  • 8. Costa JML. Marsden PD. Low dose glucantime therapy in Leishmania viannia braziliensis (Lvb) infections. Revista da Sociedade Brasileira de Medicina Tropical 21:85-86, 1988.
  • 9. Dietze R, Araújo RC, Lima MLR, Vexenat JA, Marsden PD, Barreto AC. Ensaio terapêutico com glucantime em sagüis (Callithrix jacchus) infectados com uma cepa de Leishmania donovani aparentemente resistente ao tratamento. Revista da Sociedade Brasileira de Medicina Tropical 18:39- 42, 1985.
  • 10. Figueiredo Y, Costa CA, Mayrink W, Araújo FG, Dias M, Melo MN, Magalhães P, Willians P, Batista SM, Coelho MV. Nutrição e metabolismo de formas de cultura de Leishmania Revista do Instituto de Medicina Tropical de São Paulo 18:306-314, 1976.
  • 11. Grogl M, Oduola AMJ, Cordero LDC, Kyle DE. Leishmania spp: developmentof pentostam-resistant clones in vitro by discontinuous drug exposure. Experimental Parasitology 69:78-90, 1989.
  • 12. Marsden PD. New light on pentavalent antimoniais in the treatment of leishmaniasis. Revista da Sociedade Brasileira de Medicina Tropical 16:172- 174, 1983.
  • 13. Marsden PD. Pentavalent antimoniais: Old drugs for new diseases. Revista da Sociedade Brasileira de Medicina Tropical 18:187-198, 1985.
  • 14. Marsden PD, Sampaio RNR, Carvalho EM, Veiga JPT, Costa JLM, Llanos-Cuentas EA, High continuous antimony therapy in two patients with unresponsive mucosal leishmaniasis. American Journal of Tropical Medicine and Hygiene 34:710- 713, 1985.
  • 15. Miranda-Vilela AL. Aspectos genéticosda resistência ao antimoniato de N-metilglucamina (glucantime) em formas promastigotas de Leishmania Tese de mestrado. Universidade Federal de Minas Gerais, Minas Gerais, 1991.
  • 16. Moreira ESA, Petrillo-Peixoto ML. In vitro activity of meglumine antimoniate, a pentavalent antimonial drug, on Leishmania promastigotes. The Brazilian Journal of Medical and Biological Research 24:459- 469, 1991.
  • 17. Rocha RAA, Sampaio RN, Guerra M, Magalhães A, Cuba CC, Barreto AC, Marsden PD. Apparent glucantime failure in five patients with mucocutaneous leismaniasis. Journal of Tropical Medicine and Hygiene 83:131-139, 1980.
  • 18. Ullman B, Carrero-Valenzuela E, Coons T. Leishmania donovani: isolationand characterization of sodium stiboglucanate (Pentostam)-resistant cell lines. Experimental Parasitology 69:157-163,1989.
  • 19. Verdejo J, Alvar J, Polo RM, Gonzales-Lahoz JM. Glucantime-resitant visceral leishmaniasis in immunocompromissed patients. The American Journal of Medicine 8:128, 1988.
  • Adress to correspondence:

    Dra. Elizabeth S.A. Moreira.
    Laboratório de Biologia de Microbiologia/ICB/UFMG
    CP: 2486
    31271- 970
    Belo Horizonte, MG
  • Publication Dates

    • Publication in this collection
      19 Apr 2013
    • Date of issue
      Dec 1992

    History

    • Accepted
      28 May 1992
    • Received
      28 May 1992
    Sociedade Brasileira de Medicina Tropical - SBMT Caixa Postal 118, 38001-970 Uberaba MG Brazil, Tel.: +55 34 3318-5255 / +55 34 3318-5636/ +55 34 3318-5287, http://rsbmt.org.br/ - Uberaba - MG - Brazil
    E-mail: rsbmt@uftm.edu.br